Printer Friendly

Getting the disease-modifying drugs in the U.K. (in box).

I have a good friend who lives in the U.K. who has MS, as I have. Over the last eight years she has been treated (or rather not treated) horribly. She has finally seen a neurologist (twice in the last five years) who has taken an interest in her and recommended her to take part in a drug trial. Your article confirmed that the conditions are truly bad in the U.K.

Thea Amr, via e-mail

We are all hopeful that the recent changes by Britain's National Health Service--especially the decision to cover prescriptions for all four of the disease-modifying drugs--will alter this for people in the U.K.

--the Editor
COPYRIGHT 2002 National Multiple Sclerosis Society
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Amr, Thea
Publication:Inside MS
Article Type:Letter to the Editor
Date:Oct 1, 2002
Previous Article:A new look. (heads up).
Next Article:MS and life expectancy. (in box).

Related Articles
Eugene woman's efforts give afflicted hope.
Phillips Health signs "nutritional pioneer" for new health newsletter. (Launches).
Getting disease-modifying drugs in the U.S.
Getting disease-modifying drugs in the U.K.
Hank, the man, was a far different person than Hank, the ballplayer. (Here Below).
NEPA members "holding their own" and industry sees brisk activity in newsletter launches.
It's official: Medicare covers Avonex. (news).
Immune-system injuries prompt suits over arthritis drugs.
Sosei UK Subsidiary Starts Phase IIb Clinical Trial of AD 452, Investigational Drug for Treating Rheumatoid Arthritis.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters